Systemic Lupus Erythematosus - Market Insight, Epidemiology and Market Forecast - 2027

  • ID: 4436377
  • Drug Pipelines
  • 128 pages
  • DelveInsight
1 of 3
The ‘Systemic Lupus Erythematosus (SLE) - Market Insights, Epidemiology and Market Forecast-2027’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of SLE in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.

The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Systemic Lupus Erythematosus (SLE) from 2016 to 2027 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Geography Covered
  • The United States
  • EU5 (Germany, France, Italy, Spain and the United Kingdom)
  • Japan
Study Period: 2016-2027

Systemic Lupus Erythematosus- Disease Understanding and Treatment Algorithm

The Systemic Lupus Erythematosus market report gives the thorough understanding of the Systemic Lupus Erythematosus by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Systemic Lupus Erythematosus in the US, Europe, and Japan.

Systemic Lupus Erythematosus Epidemiology

The Systemic Lupus Erythematosus (SLE) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of The report also provides the diagnosed and treatable patient pool and their trends along with assumptions undertaken.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (total prevalent cases, sex-specific prevalent cases, Lupus Nephritis prevalent cases, diagnosed cases and treatable cases) scenario of Systemic Lupus Erythematosus (SLE) in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2016-2027.

According to the report, the total number of prevalent and diagnosed population of Systemic Lupus Erythematosus (SLE) was found to be more than 5, 76,232 and 850,000 in 7MM respectively, in the year 2016.

Systemic Lupus Erythematosus Drug Chapters

This segment of the Systemic Lupus Erythematosus report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

More than five decades ago, an antimalarial drug, Plaquenil (Hydrochloroquine; Sanofi-Aventis) was approved by USFDA in 1955 for the treatment of SLE. Since then, no drug received approval for SLE treatment until 2011, when GlaxoSmithKline came up with first ever targeted therapy for the treatment of SLE, Benlysta (Belimumab). Detailed chapter for Benlysta, along with the upcoming therapies i.e., Anifrolumab (AstraZeneca), Lupuzor (ImmuPharma), Atacicept (Merck KgaA), IFNα KINOID (Neovacs), Vobarilizumab (Ablynx-Abbvie), CC-220 (Celgene) and Ustekinumab (Janssen Research & Development) have been covered in the report.

Systemic Lupus Erythematosus Market Outlook

The Systemic Lupus Erythematosus market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to the report, the market of Systemic Lupus Erythematosus in 7MM was found to be more than USD 720 million in 2016, and is expected to increase from 2016-2027.

Systemic Lupus Erythematosus Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2016-2027. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Systemic Lupus Erythematosus Report Insights
  • Patient Population
  • Therapeutic Approaches
  • Pipeline Analysis
  • Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies
Systemic Lupus Erythematosus Report Key Strengths
  • 10 Year Forecast
  • 7MM Coverage
  • Epidemiology Segmentation
  • Drugs Uptake
  • Highly Analyzed Market
  • Key Cross Competition
Systemic Lupus Erythematosus Report Assessment
  • Current Treatment Practices
  • Unmet Needs
  • Detailed Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers
Key Benefits
  • This report will help to develop Business Strategies by understanding the trends shaping and driving the Systemic Lupus Erythematosus market
  • Organize sales and marketing efforts by identifying the best opportunities for Systemic Lupus Erythematosus market
  • To understand the future market competition in the Systemic Lupus Erythematosus market.
READ MORE
Note: Product cover images may vary from those shown
2 of 3
1. Report Introduction

2. Systemic Lupus Erythematosus (SLE) Market Overview at a Glance
2.1. Market Share Distribution of Systemic Lupus Erythematosus (SLE) in 2017
2.2. Market Share Distribution of Systemic Lupus Erythematosus (SLE) in 2027
2.3. Total Prevalent Cases of Systemic Lupus Erythematosus (SLE) - by Country (2017)
2.4. Total Market by Region of Systemic Lupus Erythematosus (SLE) (2017 & 2027)

3. Disease Background and Overview: Systemic Lupus Erythematosus (SLE)
3.1. Introduction
3.2. Risk Factors
3.3. Causes
3.4. Symptoms
3.5. Clinical Manifestations
3.6. Pathogenesis
3.7. Diagnosis

4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Population and Forecast Parameters
4.3. Prevalent Population of Systemic Lupus Erythematosus (SLE) in 7MM
4.4. Prevalent Population of Systemic Lupus Erythematosus (SLE) in 7MM – By Region
4.5. Prevalent Population of Systemic Lupus Erythematosus (SLE) in 7MM – Distribution (2017)
4.6. Prevalent Population of Systemic Lupus Erythematosus (SLE) in 7MM – Distribution (2027)

5. Epidemiology of Systemic Lupus Erythematosus (SLE)
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent Population of Systemic Lupus Erythematosus (SLE) in United States
5.1.3. Diagnosed Population of Systemic Lupus Erythematosus (SLE) in United States
5.1.4. Treatable Population of Systemic Lupus Erythematosus (SLE) in United States
5.1.5. Sex-Specific Prevalence of Systemic Lupus Erythematosus (SLE) in United States
5.1.6. Prevalence of Lupus Nephritis (LN) in United States
5.2. Germany
5.2.1. Assumptions and Rationale
5.2.2. Prevalent Population of Systemic Lupus Erythematosus (SLE) (AK) in Germany
5.2.3. Diagnosed Population of Systemic Lupus Erythematosus (SLE) in Germany
5.2.4. Treatable Population of Systemic Lupus Erythematosus (SLE) in Germany
5.2.5. Sex-Specific Prevalence of Systemic Lupus Erythematosus (SLE) in Germany
5.2.6. Prevalence of Lupus Nephritis (LN) in Germany
5.3. France
5.3.1. Assumptions and Rationale
5.3.2. Prevalent Population of Systemic Lupus Erythematosus (SLE) in France
5.3.3. Diagnosed Population of Systemic Lupus Erythematosus (SLE) in France
5.3.4. Treatable Population of Systemic Lupus Erythematosus (SLE) in France
5.3.5. Sex-Specific Prevalence of Systemic Lupus Erythematosus (SLE) in France
5.3.6. Prevalence of Lupus Nephritis (LN) in France
5.4. Italy
5.4.1. Assumptions and Rationale
5.4.2. Prevalent Population of Systemic Lupus Erythematosus (SLE) in Italy
5.4.3. Diagnosed Population of Systemic Lupus Erythematosus (SLE) in Italy
5.4.4. Treatable Population of Systemic Lupus Erythematosus (SLE) in Italy
5.4.5. Sex-Specific Prevalence of Systemic Lupus Erythematosus (SLE) in Italy
5.4.6. Prevalence of Lupus Nephritis (LN) in Italy
5.5. Spain
5.5.1. Assumptions and Rationale
5.5.2. Prevalent Population of Systemic Lupus Erythematosus (SLE) in Spain
5.5.3. Diagnosed Population of Systemic Lupus Erythematosus (SLE) in Spain
5.5.4. Treatable Population of Systemic Lupus Erythematosus (SLE) in Spain
5.5.5. Sex-Specific Prevalence of Systemic Lupus Erythematosus (SLE) in Spain
5.5.6. Prevalence of Lupus Nephritis (LN) in Spain
5.6. United Kingdom
5.6.1. Assumptions and Rationale
5.6.2. Prevalent Population of Systemic Lupus Erythematosus (SLE) in United Kingdom
5.6.3. Diagnosed Population of Systemic Lupus Erythematosus (SLE) in United Kingdom
5.6.4. Treatable Population of Systemic Lupus Erythematosus (SLE) in United Kingdom
5.6.5. Sex-Specific Prevalence of Systemic Lupus Erythematosus (SLE) in United Kingdom
5.6.6. Prevalence of Lupus Nephritis (LN) in United Kingdom
5.7. Japan
5.7.1. Assumptions and Rationale
5.7.2. Prevalent Population of Systemic Lupus Erythematosus (SLE) in Japan
5.7.3. Diagnosed Population of Systemic Lupus Erythematosus (SLE) in Japan
5.7.4. Treatable Population of Systemic Lupus Erythematosus (SLE) in Japan
5.7.5. Sex-Specific Prevalence of Systemic Lupus Erythematosus (SLE) in Japan
5.7.6. Prevalence of Lupus Nephritis (LN) in Japan

6. Treatment Practices
6.1. Treatment Goals
6.2. Treatment Algorithm

7. Unmet Needs

8. Marketed Drugs
8.1. Benlysta: GlaxoSmithKline plc
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Safety and Efficacy of Benlysta
8.1.6. Product Profile

9. Emerging Therapies
9.1. Key Cross Competition
9.2. Phase III Drugs
9.2.1. Lupuzor: Immupharma
9.2.1.1. Regulatory Milestones
9.2.1.2. Other development activities
9.2.1.3. Clinical Development
9.2.1.4. Clinical Trials Information
9.2.1.5. Safety and Efficacy
9.2.1.6. Product Profile
9.2.2. Anifrolumab: AstraZeneca
9.2.2.1. Regulatory Milestones
9.2.2.2. Other development activities
9.2.2.3. Clinical Development
9.2.2.4. Clinical Trials Information
9.2.2.5. Safety and Efficacy
9.2.2.6. Product Profile
9.3. Phase II Drugs
9.3.1. Atacicept: Merck KgaA
9.3.1.1. Other development activities
9.3.1.2. Clinical Development
9.3.1.3. Clinical Trials Information
9.3.1.4. Safety and Efficacy
9.3.1.5. Product Profile
9.3.2. IFNα Kinoid: Neovacs
9.3.2.1. Regulatory Milestones
9.3.2.2. Other development activities
9.3.2.3. Clinical Development
9.3.2.4. Clinical Trials Information
9.3.2.5. Safety and Efficacy
9.3.2.6. Product Profile
9.3.3. Vobarilizumab: Ablynx
9.3.3.1. Other development activities
9.3.3.2. Clinical Development
9.3.3.3. Clinical Trials Information
9.3.3.4. Safety and Efficacy
9.3.3.5. Product Profile
9.3.4. CC-220: Celgene
9.3.4.1. Clinical Development
9.3.4.2. Clinical Trials Information
9.3.4.3. Safety and Efficacy
9.3.4.4. Product Profile
9.3.5. STELARA (ustekinumab): Janssen Research & Development
9.3.5.1. Clinical Development
9.3.5.2. Clinical Trials Information
9.3.5.3. Safety and Efficacy
9.3.5.4. Product Profile

10. Market Size of Systemic Lupus Erythematosus for 7MM
10.1. SLE Market Share by Therapies for 7MM
10.2. United States-SLE Market Size
10.3. EU-5-SLE Market Size
10.3.1. Germany-SLE Market Size
10.3.2. France-SLE Market Size
10.3.3. Italy-SLE Market Size
10.3.4. Spain-SLE Market Size
10.3.5. United Kingdom-SLE Market Size
10.4. Japan-SLE Market Size

11. Market Drivers

12. Market Barriers

13. Appendix

14. Report Methodology
14.1. Sources Used

15. Publisher Capabilities

16. Disclaimer

17. About the Publisher

List of Tables:
Table 1: Major clinical manifestations of Systemic Lupus Erythematosus (SLE)
Table 2: THE 1982 REVISED CRITERIA FOR CLASSIFICATION OF SYSTEMIC LUPUS ERYTHEMATOSUS
Table 3: Differential Diagnosis of Systemic Lupus Erythematosus
Table 4: Diagnostic Criteria for Systemic Lupus Erythematosus
Table 5: Diagnostic Tests for Systemic Lupus Erythematosus
Table 6: Total Prevalent Population of Systemic Lupus Erythematosus (SLE) in 7 MM (2016-2027)
Table 7: Prevalent Population of Systemic Lupus Erythematosus (SLE) in 7MM (2016-2027)
Table 8: Prevalent Population of Systemic Lupus Erythematosus (SLE) in United States (2016-2027)
Table 9: Diagnosed Population of Systemic Lupus Erythematosus (SLE) in United States (2016-2027)
Table 10: Treatable Population of Systemic Lupus Erythematosus (SLE) in United States (2016-2027)
Table 11: Sex-Specific Distribution of Systemic Lupus Erythematosus (SLE) in United States (2017)
Table 12: Prevalent Population of Lupus Nephritis (LN) in United States (2016-2027)
Table 13: Prevalent Population of Systemic Lupus Erythematosus (SLE) in Germany (2016-2027)
Table 14: Diagnosed Population of Systemic Lupus Erythematosus (SLE) in Germany (2016-2027)
Table 15: Treatable Population of Systemic Lupus Erythematosus (SLE) in Germany (2016-2027)
Table 16: Sex-Specific Prevalent Distribution of Systemic Lupus Erythematosus (SLE) in Germany (2017)
Table 17: Prevalent Population of Lupus Nephritis (LN) in Germany (2016-2027)
Table 18: Prevalent Population of Systemic Lupus Erythematosus (SLE) in France (2016-2027)
Table 19: Diagnosed Population of Systemic Lupus Erythematosus (SLE) in France (2016-2027)
Table 20: Treatable Population of Systemic Lupus Erythematosus (SLE) in France (2016-2027)
Table 21: Sex-Specific Prevalent Population of Systemic Lupus Erythematosus (SLE) in France (2017)
Table 22: Prevalent Population of Lupus Nephritis (LN) in France (2016-2027)
Table 23: Prevalent Population of Systemic Lupus Erythematosus (SLE) in Italy (2016-2027)
Table 24: Diagnosed Population of Systemic Lupus Erythematosus (SLE) in Italy (2016-2027)
Table 25: Treatable Population of Systemic Lupus Erythematosus (SLE) in Italy (2016-2027)
Table 26: Sex-Specific Prevalent Distribution of Systemic Lupus Erythematosus (SLE) in Italy (2017)
Table 27: Prevalent Population of Lupus Nephritis (LN) in Italy (2016-2027)
Table 28: Prevalent Population of Systemic Lupus Erythematosus (SLE) in Spain (2016-2027)
Table 29: Diagnosed Population of Systemic Lupus Erythematosus (SLE) in Spain (2016-2027)
Table 30: Treatable Population of Systemic Lupus Erythematosus (SLE) in Spain (2016-2027)
Table 31: Sex-Specific Prevalent Population of Systemic Lupus Erythematosus (SLE) in Spain (2017)
Table 32: Prevalent Population of Lupus Nephritis (LN) in Spain (2016-2027)
Table 33: Prevalent Population of Systemic Lupus Erythematosus (SLE) in UK (2016-2027)
Table 34: Diagnosed Population of Systemic Lupus Erythematosus (SLE) in UK (2016-2027)
Table 35: Treatable Population of Systemic Lupus Erythematosus (SLE) in UK (2016-2027)
Table 36: Sex-Specific Prevalent Distribution of Systemic Lupus Erythematosus (SLE) in UK (2017)
Table 37: Prevalent Population of Lupus Nephritis (LN) in United Kingdom (2016-2027)
Table 38: Prevalent Population of Systemic Lupus Erythematosus (SLE) in Japan (2016-2027)
Table 39: Diagnosed Population of Systemic Lupus Erythematosus (SLE) in Japan (2016-2027)
Table 40: Treatable Population of Systemic Lupus Erythematosus (SLE) in Japan (2016-2027)
Table 41: Sex-Specific Prevalent Distribution of Systemic Lupus Erythematosus (SLE) in Japan (2017)
Table 42: Prevalent Population of Lupus Nephritis (LN) in Japan (2016-2027)
Table 43: Comparison of emerging drugs under development
Table 44: Comparison of emerging drugs under development
Table 45: Emerging drugs: Safety and Efficacy
Table 46: Lupuzor, Clinical Trial Description, 2018
Table 47: Anifrolumab, Clinical Trial Description, 2018
Table 48: Atacicept, Clinical Trial Description, 2018
Table 49: Lupuzor, Clinical Trial Description, 2018
Table 50: ALX0061, Clinical Trial Description, 2018
Table 51: CC-220, Clinical Trial Description, 2018
Table 52: Lupuzor, Clinical Trial Description, 2018
Table 53: Market Size of Systemic Lupus Erythematosus (SLE) in 7MM in USD, Million (2016-2027)
Table 54: US Market Size of Systemic Lupus Erythematosus (SLE) in USD, Million (2016-2027)
Table 55: Germany Market Size of Systemic Lupus Erythematosus (SLE) in USD, Million (2016-2027)
Table 56: France Market Size of Systemic Lupus Erythematosus (SLE) in USD, Million (2016-2027)
Table 57: Italy Market Size of Systemic Lupus Erythematosus (SLE) in USD, Million (2016-2027)
Table 58: Spain Market Size of Systemic Lupus Erythematosus (SLE) in USD, Million (2016-2027)
Table 59: UK Market Size of Systemic Lupus Erythematosus (SLE) in USD, Million (2016-2027)
Table 60:Japan Market Size of Systemic Lupus Erythematosus (SLE) in USD, Million (2016-2027)

List of Figures:
Figure 1: Risk Factors of SLE
Figure 2: Pathogenesis of Systemic Lupus Erythematosus
Figure 3: Algorithm for diagnosis of Systemic Lupus Erythematosus
Figure 4: Total Prevalent Population of Systemic Lupus Erythematosus (SLE) in 7 MM (2016-2027)
Figure 5: Prevalent Population of Systemic Lupus Erythematosus (SLE) in 7MM (2016-2027)
Figure 6: Prevalent Population of Systemic Lupus Erythematosus (SLE) in US (2016-2027)
Figure 7: Diagnosed Population of Systemic Lupus Erythematosus (SLE) in US (2016-2027)
Figure 8:Treatable Population of Systemic Lupus Erythematosus (SLE) in US (2016-2027)
Figure 9: Sex- Specific Prevalent Distribution of Systemic Lupus Erythematosus (SLE) in US (2017)
Figure 10: Prevalent Population of Lupus Nephritis in United States (2016-2027)
Figure 11: Prevalent Population of Systemic Lupus Erythematosus (SLE) in Germany (2016-2027)
Figure 12: Diagnosed Population of Systemic Lupus Erythematosus (SLE) in Germany (2016-2027)
Figure 13:Treatable Population of Systemic Lupus Erythematosus (SLE) in Germany (2016-2027)
Figure 14: Sex- Specific Prevalent Distribution of Systemic Lupus Erythematosus (SLE) in Germany (2017)
Figure 15: Prevalent Population of Lupus Nephritis in Germany (2016-2027)
Figure 16: Prevalent Population of Systemic Lupus Erythematosus (SLE) in France (2016-2027)
Figure 17: Diagnosed Population of Systemic Lupus Erythematosus (SLE) in France (2016-2027)
Figure 18:Treatable Population of Systemic Lupus Erythematosus (SLE) in France (2016-2027)
Figure 19: Sex- Specific Prevalent Population of Systemic Lupus Erythematosus (SLE) in France (2017)
Figure 20: Prevalent Population of Lupus Nephritis in France (2016-2027)
Figure 21: Prevalent Population of Systemic Lupus Erythematosus (SLE) in Italy (2016-2027)
Figure 22: Diagnosed Population of Systemic Lupus Erythematosus (SLE) in Italy (2016-2027)
Figure 23:Treatable Population of Systemic Lupus Erythematosus (SLE) in Italy (2016-2027)
Figure 24: Sex- Specific Prevalent Distribution of Systemic Lupus Erythematosus (SLE) in Italy (2017)
Figure 25: Prevalent Population of Lupus Nephritis in Italy (2016-2027)
Figure 26: Prevalent Population of Systemic Lupus Erythematosus (SLE) in Spain (2016-2027)
Figure 27: Diagnosed Population of Systemic Lupus Erythematosus (SLE) in Spain (2016-2027)
Figure 28:Treatable Population of Systemic Lupus Erythematosus (SLE) in Spain (2016-2027)
Figure 29: Sex- Specific Prevalent Population of Systemic Lupus Erythematosus (SLE) in Spain (2017)
Figure 30: Prevalent Population of Lupus Nephritis in Spain (2016-2027)
Figure 31: Prevalent Population of Systemic Lupus Erythematosus (SLE) in UK (2016-2027)
Figure 32: Diagnosed Population of Systemic Lupus Erythematosus (SLE) in UK (2016-2027)
Figure 33:Treatable Population of Systemic Lupus Erythematosus (SLE) in UK (2016-2027)
Figure 34: Sex- Specific Prevalent Distribution of Systemic Lupus Erythematosus (SLE) in UK (2017)
Figure 35: Prevalent Population of Lupus Nephritis in United Kingdom (2016-2027)
Figure 36: Prevalent Population of Systemic Lupus Erythematosus (SLE) in Japan (2016-2027)
Figure 37: Diagnosed Population of Systemic Lupus Erythematosus (SLE) in Japan (2016-2027)
Figure 38:Treatable Population of Systemic Lupus Erythematosus (SLE) in Japan (2016-2027)
Figure 39: Sex- Specific Prevalent Distribution of Systemic Lupus Erythematosus (SLE) in Japan (2017)
Figure 40: Prevalent Population of Lupus Nephritis in Japan (2016-2027)
Figure 41: Market Size of Systemic Lupus Erythematosus (SLE) in 7MM, in USD, Million (2016-2027)
Figure 42: US Market Size of Systemic Lupus Erythematosus (SLE) in USD, Million (2016-2027)
Figure 43: Germany Market Size of Systemic Lupus Erythematosus (SLE) in USD, Million (2016-2027)
Figure 44: France Market Size of Systemic Lupus Erythematosus (SLE) in USD, Million (2016-2027)
Figure 45: Italy Market Size of Systemic Lupus Erythematosus (SLE) in USD, Million (2016-2027)
Figure 46: Spain Market Size of Systemic Lupus Erythematosus (SLE) in USD, Million (2016-2027)
Figure 47: UK Market Size of Systemic Lupus Erythematosus (SLE) in USD, Million (2016-2027)
Figure 48: Japan Market Size of Systemic Lupus Erythematosus (SLE) in USD, Million (2016-2027)
Figure 49: Market Drivers
Figure 50: Market Barriers
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll